ImmunityBio
(NASDAQ) IBRX
ImmunityBio Financials at a Glance
Market Cap
$7.25B
Revenue (TTM)
$140.98M
Net Income (TTM)
-$854.53M
EPS (TTM)
-$0.85
P/E Ratio
-8.10
Dividend
$0.00
Beta (Volatility)
2.17 (High)
Dividend
$0.00
Beta (Volatility)
2.17 (High)
Price
$6.95
Volume
13,818,425.857
Open
$7.15
Price
$6.95
Volume
13,818,425.857
Open
$7.15
Previous Close
$6.92
Daily Range
$6.79 - $7.29
52-Week Range
$1.95 - $12.43
Estimated Earnings Date
Aug 4, 2026
Dividend
$0.00
Beta (Volatility)
2.17 (High)
Price
$6.95
Volume
13,818,425.857
Open
$7.15
Previous Close
$6.92
Daily Range
$6.79 - $7.29
52-Week Range
$1.95 - $12.43
Estimated Earnings Date
Aug 4, 2026
IBRX News
IBRX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout ImmunityBio
Industry
Biotechnology
Sector
Health CareEmployees
691
CEO
Richard Adcock, MBA
Website
www.immunitybio.comHeadquarters
San Diego, CA 92121, US
IBRX Financials
Key Financial Metrics (TTM)
Gross Margin
94%
Operating Margin
-2%
Net Income Margin
-6%
Return on Equity
0%
Return on Capital
-45%
Return on Assets
-1%
Earnings Yield
-12.35%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$7.25B
Shares Outstanding
1.05B
Volume
13.82M
Avg. Volume
17.85M
Financials (TTM)
Gross Profit
$112.54M
Operating Income
-$256.03M
EBITDA
-$223.56M
Operating Cash Flow
-$304.94M
Capital Expenditure
-$3.85M
Free Cash Flow
-$308.78M
Cash & ST Invst.
$242.82M
Total Debt
$878.12M
ImmunityBio Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$44.21M
+167.6%
Gross Profit
$43.97M
+167.1%
Gross Margin
99.46%
N/A
Market Cap
$7.25B
N/A
Market Cap/Employee
$10.80M
N/A
Employees
671
N/A
Net Income
-$632.78M
-388.1%
EBITDA
-$65.41M
+32.7%
Quarterly Fundamentals
Net Cash
-$743.73M
-60.1%
Accounts Receivable
$43.27M
+147.9%
Inventory
$547.00K
-93.5%
Long Term Debt
$1.12B
+115.1%
Short Term Debt
$8.56M
+14.8%
Return on Assets
-1.32%
N/A
Return on Invested Capital
-45.17%
N/A
Free Cash Flow
-$77.15M
+11.4%
Operating Cash Flow
-$75.36M
+12.3%